A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients ("ABBY")
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Abemaciclib (Primary) ; Hydroxychloroquine (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ABBY
- 02 Nov 2021 Status changed from not yet recruiting to recruiting.
- 01 Oct 2021 Planned initiation date changed from 1 Aug 2021 to 18 Oct 2021.
- 19 Jul 2021 Planned initiation date changed from 1 Apr 2021 to 1 Aug 2021.